Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

cardiovascular system
Marea hopes ANGPTL4 inhibition can benefit high-risk cardiovascular patients • Source: Shutterstock

More from Strategy

More from R&D